Weekly highlight of top insider buys: General Motors Company (GM, Financial), Celgene Corp. (CELG, Financial), Chesapeake Energy Corp. (CHK, Financial), Valeant Pharmaceuticals International (VRX, Financial), and Marvell Technology Group Ltd. (MRVL, Financial).
General Motors Company (GM): Director Robert D Krebs Bought 5,000 Shares
Director of General Motors Company, Robert D Krebs, bought 5,000 shares on 3/10/2011 at an average price of $31.85.
General Motors Company is engaged in the designing, manufacturing and retailing of vehicles globally including passenger cars, crossover vehicles, and light trucks, sport utility vehicles, vans and other vehicles. General Motors Company has a market cap of $49.71 billion; its shares were traded at around $31.85 with and P/S ratio of 0.4.
General Motors Company (NYSE: GM) today announced its calendar year 2010 results marked by $4.7 billion of net income attributable to common stockholders for its first full year of operations.
On February 24, General Motors Company reported results for the first full year of operations. Revenue for the calendar year was $135.6 billion. Automotive cash flow from operating activities was $6.6 billion and automotive free cash flow was $2.4 billion, both reflecting the impact of a $4.0 billion voluntary cash contribution to the company’s U.S. pension plans.
General Motors Company is in the portfolios of Bill Ackman, Richard Perry, David Tepper, NWQ Managers, Brian Rogers, John Griffin, George Soros, Third Avenue Management, Ken Heebner, Arnold Shneider, Ronald Muhlenkamp, Jean-Marie Eveillard, and Mario Gabelli.
This month, Buy: CEO Daniel F Akerson, Buy: Director Robert D Krebs, Buy: Director Philip A Laskawy, and Buy: Director E Neville Isdell bought shares of GM stock. color=green]Buy:[/color] Vice President Joel Ewanick and Buy: Vice President Selim Bingol bought shares in November.
Celgene Corp. (CELG): Director Ernest Mario Bought 2,500 Shares
Director of Celgene Corp., Ernest Mario, bought 2,500 shares on 3/15/2011 at an average price of $52.98.
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $24.63 billion; its shares were traded at around $52.98 with a P/E ratio of 21.7 and P/S ratio of 6.8.
On January 27, Celgene Corporation announced non-GAAP net income of $347.6 million, or non-GAAP diluted earnings per share of $0.73 for the quarter ended December 31, 2010. Non-GAAP net income for the fourth quarter of 2009 was $290.3 million or non-GAAP diluted earnings per share of $0.62. Based on U.S. GAAP, Celgene reported net income of $213.6 million, or diluted earnings per share of $0.45 for the quarter ended December 31, 2010. GAAP net income for the fourth quarter of 2009 was $254.2 million, or diluted earnings per share of $0.54.
Buy: Director Ernest Mario bought 2,500 shares of CELG stock last week. He also bought shares in January Sell: Director Sol J Barer sold 75,200 shares in January; Sell: Director Walter L Robb sold 5,900 shares in November
Chesapeake Energy Corp. (CHK): Director Richard K Davidson Bought 20,000 Shares
Director of Chesapeake Energy Corp., Richard K Davidson, bought 20,000 shares on 3/10/2011 at an average price of $33.37.
Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake Energy Corp. has a market cap of $21.95 billion; its shares were traded at around $33.37 with a P/E ratio of 11.2 and P/S ratio of 2.5. The dividend yield of Chesapeake Energy Corp. stocks is 0.9%. Chesapeake Energy Corp. had an annual average earnings growth of 14.7% over the past 10 years. GuruFocus rated Chesapeake Energy Corp. the business predictability rank of 2-star.
On March 1, Chesapeake Midstream Partners, L.P. announced financial results for the 2010 fourth quarter. Net income for the 2010 fourth quarter totaled $89.9 million, an increase of $39.2 million versus the 2009 fourth quarter. The Partnership's adjusted ebitda for the 2010 fourth quarter was $115.6 million and distributable cash flow ("DCF") was $96.7 million. Financial terms are defined on page 3 of this release. Fourth quarter results include operations of the Springridge assets from the closing of the acquisition on December 21, 2010 through the end of the year as well as associated transaction costs. DCF for the 2010 full year resulted in a 1.15 coverage ratio as compared to the minimum quarterly distribution.
Chesapeake Energy Corp. is in the portfolios of Richard Snow, Carl Icahn, T Boone Pickens, Arnold Shneider, David Dreman, Ronald Muhlenkamp, Mario Gabelli, Ruane Cunniff, and Charles Brandes.
Buy: Chairman & CEO Aubrey K Mcclendon, Buy: Director V Burns Hargis,
Buy: Director Richard K Davidson, and Buy: Director Merrill A Jr Miller bought shares of CHK stock this month. Buy: Director V Burns Hargis bought 2,310 shares in December.
Valeant Pharmaceuticals International (VRX): Director Katharine Berghuis Stevenson Bought 2,000 Shares
Director of Valeant Pharmaceuticals International, Katharine Berghuis, Stevenson bought 2,000 shares on 3/14/2011 at an average price of $39.89.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International has a market cap of $12.14 billion; its shares were traded at around $39.89 with a P/E ratio of 36.3 and P/S ratio of 10.3. The dividend yield of Valeant Pharmaceuticals International stocks is 0.7%. Valeant Pharmaceuticals International had an annual average earnings growth of 10.8% over the past 5 years.
On February 24, Valeant Pharmaceuticals International reported results for the fourth quarter of 2010. Total reported revenue was $514.6 million in the fourth quarter of 2010 as compared to $241.1 million in the fourth quarter of 2009. Product sales were $488.7 million in the fourth quarter of 2010, as compared to $231.6 million in the year-ago quarter. These increases are primarily due to the acquisition of Valeant Pharmaceuticals International (Legacy Valeant) by Biovail Corporation (Legacy Biovail), which was completed in September 2010.
Valeant Pharmaceuticals International is in the portfolios of Julian Robertson, George Soros, NWQ Managers, Andreas Halvorsen, Jean-Marie Eveillard, John Griffin, Ruane Cunniff, John Hussman, and Private Capital.
Buy: Director Katharine Berghuis Stevenson and Buy: Director Norma Ann Provencio bought shares of VRX stock this month. Sell: Holdings, L.p. Valueact sold 7,366,419 shares this month. Sell: Director Robert Alexander Ingram sold 9,872 shares in February.
Marvell Technology Group Ltd. (MRVL): Director John G Kassakian Bought 2,000 Shares
Director of Marvell Technology Group Ltd., John G Kassakian, bought 2,000 shares on 3/10/2011 at an average price of $15.62.
Marvell Technology is a designer, developer and supplier of mixed-signal and digital signal processing integrated circuit for high-speed, high-density, digital data storage and broadband digital data networking markets. Marvell Technology Group Ltd. has a market cap of $10.16 billion; its shares were traded at around $15.62 with a P/E ratio of 10.5 and P/S ratio of 2.8. Marvell Technology Group Ltd. had an annual average earnings growth of 34% over the past 10 years.
On Mar 3, Marvell reported financial results for the fourth fiscal quarter and fiscal year 2011, ended January 29, 2011.Revenue for the fourth quarter of fiscal 2011 was $901 million, a 7 percent increase from $843 million in the fourth quarter of fiscal 2010, ended January 30, 2010, and a 6 percent sequential decrease from $959 million in the third quarter of fiscal 2011, ended October 30, 2010. For the fiscal year ended January 29, 2011, revenue was $3.61 billion, an increase of 29 percent over revenue of $2.81 billion for the fiscal year ended January 30, 2010. GAAP net income for the fourth quarter of fiscal 2011 was $223 million, or $0.33 per share (diluted), compared with GAAP net income of $205 million, or $0.31 per share (diluted) for the fourth quarter of fiscal 2010. GAAP net income in the third quarter of fiscal 2011 was $256 million, or $0.38 per share (diluted). Marvell Technology Group is in the portfolios of Joel Greenblatt, George Soros, and Lee Ainslie.
This month, Buy: Director John G Kassakian bought 2,000 shares of MRVL stock.
For the complete list of stocks that bought by their company executives, go to: Insider Buys.
General Motors Company (GM): Director Robert D Krebs Bought 5,000 Shares
Director of General Motors Company, Robert D Krebs, bought 5,000 shares on 3/10/2011 at an average price of $31.85.
General Motors Company is engaged in the designing, manufacturing and retailing of vehicles globally including passenger cars, crossover vehicles, and light trucks, sport utility vehicles, vans and other vehicles. General Motors Company has a market cap of $49.71 billion; its shares were traded at around $31.85 with and P/S ratio of 0.4.
General Motors Company (NYSE: GM) today announced its calendar year 2010 results marked by $4.7 billion of net income attributable to common stockholders for its first full year of operations.
On February 24, General Motors Company reported results for the first full year of operations. Revenue for the calendar year was $135.6 billion. Automotive cash flow from operating activities was $6.6 billion and automotive free cash flow was $2.4 billion, both reflecting the impact of a $4.0 billion voluntary cash contribution to the company’s U.S. pension plans.
General Motors Company is in the portfolios of Bill Ackman, Richard Perry, David Tepper, NWQ Managers, Brian Rogers, John Griffin, George Soros, Third Avenue Management, Ken Heebner, Arnold Shneider, Ronald Muhlenkamp, Jean-Marie Eveillard, and Mario Gabelli.
This month, Buy: CEO Daniel F Akerson, Buy: Director Robert D Krebs, Buy: Director Philip A Laskawy, and Buy: Director E Neville Isdell bought shares of GM stock. color=green]Buy:[/color] Vice President Joel Ewanick and Buy: Vice President Selim Bingol bought shares in November.
Celgene Corp. (CELG): Director Ernest Mario Bought 2,500 Shares
Director of Celgene Corp., Ernest Mario, bought 2,500 shares on 3/15/2011 at an average price of $52.98.
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $24.63 billion; its shares were traded at around $52.98 with a P/E ratio of 21.7 and P/S ratio of 6.8.
On January 27, Celgene Corporation announced non-GAAP net income of $347.6 million, or non-GAAP diluted earnings per share of $0.73 for the quarter ended December 31, 2010. Non-GAAP net income for the fourth quarter of 2009 was $290.3 million or non-GAAP diluted earnings per share of $0.62. Based on U.S. GAAP, Celgene reported net income of $213.6 million, or diluted earnings per share of $0.45 for the quarter ended December 31, 2010. GAAP net income for the fourth quarter of 2009 was $254.2 million, or diluted earnings per share of $0.54.
Buy: Director Ernest Mario bought 2,500 shares of CELG stock last week. He also bought shares in January Sell: Director Sol J Barer sold 75,200 shares in January; Sell: Director Walter L Robb sold 5,900 shares in November
Chesapeake Energy Corp. (CHK): Director Richard K Davidson Bought 20,000 Shares
Director of Chesapeake Energy Corp., Richard K Davidson, bought 20,000 shares on 3/10/2011 at an average price of $33.37.
Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake Energy Corp. has a market cap of $21.95 billion; its shares were traded at around $33.37 with a P/E ratio of 11.2 and P/S ratio of 2.5. The dividend yield of Chesapeake Energy Corp. stocks is 0.9%. Chesapeake Energy Corp. had an annual average earnings growth of 14.7% over the past 10 years. GuruFocus rated Chesapeake Energy Corp. the business predictability rank of 2-star.
On March 1, Chesapeake Midstream Partners, L.P. announced financial results for the 2010 fourth quarter. Net income for the 2010 fourth quarter totaled $89.9 million, an increase of $39.2 million versus the 2009 fourth quarter. The Partnership's adjusted ebitda for the 2010 fourth quarter was $115.6 million and distributable cash flow ("DCF") was $96.7 million. Financial terms are defined on page 3 of this release. Fourth quarter results include operations of the Springridge assets from the closing of the acquisition on December 21, 2010 through the end of the year as well as associated transaction costs. DCF for the 2010 full year resulted in a 1.15 coverage ratio as compared to the minimum quarterly distribution.
Chesapeake Energy Corp. is in the portfolios of Richard Snow, Carl Icahn, T Boone Pickens, Arnold Shneider, David Dreman, Ronald Muhlenkamp, Mario Gabelli, Ruane Cunniff, and Charles Brandes.
Buy: Chairman & CEO Aubrey K Mcclendon, Buy: Director V Burns Hargis,
Buy: Director Richard K Davidson, and Buy: Director Merrill A Jr Miller bought shares of CHK stock this month. Buy: Director V Burns Hargis bought 2,310 shares in December.
Valeant Pharmaceuticals International (VRX): Director Katharine Berghuis Stevenson Bought 2,000 Shares
Director of Valeant Pharmaceuticals International, Katharine Berghuis, Stevenson bought 2,000 shares on 3/14/2011 at an average price of $39.89.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International has a market cap of $12.14 billion; its shares were traded at around $39.89 with a P/E ratio of 36.3 and P/S ratio of 10.3. The dividend yield of Valeant Pharmaceuticals International stocks is 0.7%. Valeant Pharmaceuticals International had an annual average earnings growth of 10.8% over the past 5 years.
On February 24, Valeant Pharmaceuticals International reported results for the fourth quarter of 2010. Total reported revenue was $514.6 million in the fourth quarter of 2010 as compared to $241.1 million in the fourth quarter of 2009. Product sales were $488.7 million in the fourth quarter of 2010, as compared to $231.6 million in the year-ago quarter. These increases are primarily due to the acquisition of Valeant Pharmaceuticals International (Legacy Valeant) by Biovail Corporation (Legacy Biovail), which was completed in September 2010.
Valeant Pharmaceuticals International is in the portfolios of Julian Robertson, George Soros, NWQ Managers, Andreas Halvorsen, Jean-Marie Eveillard, John Griffin, Ruane Cunniff, John Hussman, and Private Capital.
Buy: Director Katharine Berghuis Stevenson and Buy: Director Norma Ann Provencio bought shares of VRX stock this month. Sell: Holdings, L.p. Valueact sold 7,366,419 shares this month. Sell: Director Robert Alexander Ingram sold 9,872 shares in February.
Marvell Technology Group Ltd. (MRVL): Director John G Kassakian Bought 2,000 Shares
Director of Marvell Technology Group Ltd., John G Kassakian, bought 2,000 shares on 3/10/2011 at an average price of $15.62.
Marvell Technology is a designer, developer and supplier of mixed-signal and digital signal processing integrated circuit for high-speed, high-density, digital data storage and broadband digital data networking markets. Marvell Technology Group Ltd. has a market cap of $10.16 billion; its shares were traded at around $15.62 with a P/E ratio of 10.5 and P/S ratio of 2.8. Marvell Technology Group Ltd. had an annual average earnings growth of 34% over the past 10 years.
On Mar 3, Marvell reported financial results for the fourth fiscal quarter and fiscal year 2011, ended January 29, 2011.Revenue for the fourth quarter of fiscal 2011 was $901 million, a 7 percent increase from $843 million in the fourth quarter of fiscal 2010, ended January 30, 2010, and a 6 percent sequential decrease from $959 million in the third quarter of fiscal 2011, ended October 30, 2010. For the fiscal year ended January 29, 2011, revenue was $3.61 billion, an increase of 29 percent over revenue of $2.81 billion for the fiscal year ended January 30, 2010. GAAP net income for the fourth quarter of fiscal 2011 was $223 million, or $0.33 per share (diluted), compared with GAAP net income of $205 million, or $0.31 per share (diluted) for the fourth quarter of fiscal 2010. GAAP net income in the third quarter of fiscal 2011 was $256 million, or $0.38 per share (diluted). Marvell Technology Group is in the portfolios of Joel Greenblatt, George Soros, and Lee Ainslie.
This month, Buy: Director John G Kassakian bought 2,000 shares of MRVL stock.
For the complete list of stocks that bought by their company executives, go to: Insider Buys.
